The Morrison government will reportedly make permanent changes to the continuous disclosure laws that were introduced at the height of the COVID-19 pandemic, as part of a wider effort to crack down on class action litigation.
A bill to merge the Family Court with the Federal Circuit Court is expected to pass after independent senator Rex Patrick gave his backing on Tuesday, even as opposition to the controversial legislation mounts.
Commonwealth Bank of Australia could be on the hook for a large penalty after the court found the bank engaged in misleading and deceptive conduct and violated its financial services obligations on more than 12,000 occasions by overcharging customers more than $2.2 million in interest.
A tax agent and accountant who conducted multiple tax exploitation schemes between 2011 and 2015 has been hit with a $22.7 million penalty, the largest ever against a tax promotor.
PricewaterhouseCoopers is looking to shut down a class action by irate bondholders of collapsed asset finance lender Axsesstoday Limited over alleged misrepresentations in a $50 million bond offer.
Pharmaceutical companies Sanofi and Bristol-Myers Squibb are liable for losses to the federal government for excess subsidies it allegedly paid for the blood-thinner Plavix after an unjustified court injunction prevented the release of a generic version of the top-selling drug, an appeals court has heard.
A fraudster who robbed victims of $7.6 million by pretending to be a financial investor and barrister has had his jail sentence reduced from 16 years to 12, after a court of appeal heard his original sentence was “crushing” and did not reflect his guilty plea or lack of criminal record.
A $37.75 million settlement has been reached in a shareholder class action against Estia Health that accused the aged care provider of failing to disclose difficulties in its 2015 and 2016 acquisition strategy.
US pharmaceutical giant Merck Sharp & Dohme has taken Sandoz to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Janumet and Januvia.
GetSwift has been criticised for its “quite unfair attack” on a Federal Court judge who refused to disqualify himself from hearing a shareholder class action against the logistics software company after presiding over ASIC’s civil penalty proceeding against the company.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
